New #research from #CUAnschutz suggests that memories held within blood stem cells may trigger the often-disabling symptoms of autoimmune disease that flare up over a person’s lifetime. https://t.co/A4pS1alguU
Yesterday, @SenatorHick visited #CUAnschutz to tour the lab of cancer researcher Dr. Heide Ford. He also participated in a roundtable dicsussion about the importance of #research funding in driving lifesaving medical discoveries across our campus and country. @CUCancerCenter
We are loving Day 3 of #ASH24 with Gaslamp District of San Diego as backdrop (😍)
Evolving #hematology therapies & patient care best practices♥️♥️♥️- our pioneering work means advancing our collective understanding ♥️♥️♥️
CU @ 66th ASH Annual Meeting: https://t.co/jbJlq4woRB
From @CraigTJordanLab a fascinating story delivered by Mark Althoff. LSCs primary resistant to Ven/Aza have IRF2BP2 sequestered in the cytoplasm by MCL1 altering fatty acids metabolism. 👏
🔥 SwissCheese Ludo Challenge: Compete for $73,000! 🚀
The SwissCheese Ludo Challenge is now open, and the grand prize of $73,000 is waiting for you! 💥 It's time to level up your Cheese Miner and take on competitors for a chance to win this massive prize. 🎮🏆💰
👉 Start your Ludo journey here: https://t.co/6R8ZYMErkz
#SwissCheeseFinance #LudoChallenge #PlayToWin #CryptoGaming #BigRewards
Online Now! Post-transplant G-CSF impedes engraftment of gene-edited human hematopoietic stem cells by exacerbating p53-mediated DNA damage response https://t.co/uGrr7W7Y70 #stemcells
Dr. Minhajuddin at @CUMedicalSchool and team show that venetoclax/dasatinib is a leukemia stem cell (LSC) selective regimen in blast phase CML and that disrupting LIPA and fatty acid transport enhances venetoclax/dasatinib response in targeting LSCs.
https://t.co/HKxOvv9NLy
It's #ClinicalTrialsDay! CU Cancer Center member Maria Amaya (@MariaAmaya_27), MD, PhD, shares how clinical trials can provide better outcomes for cancer patients.
Watch the full video here: https://t.co/n96owa8jYV